# APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

> **NCT00343460** · PHASE3 · COMPLETED · sponsor: **Heron Therapeutics** · enrollment: 1428 (actual)

## Conditions studied

- Nausea and Vomiting
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** APF530
- **DRUG:** dexamethasone
- **DRUG:** Palonosetron Hydrochloride
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00343460
- **Lead sponsor:** Heron Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-09
- **Final completion:** 2009-02
- **Target enrollment:** 1428 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343460, "APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00343460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*